Ex-Sanofi Exec Stoeckli Primes Glenmark’s Cancer Therapy Ambitions
Glenmark’s president and chief scientific officer, Dr Kurt Stoeckli, believes that some big pharma companies may have missed the opportunity to embark on immunotherapy cancer treatment R&D “at the right time” and tells Scrip that there is room for the Indian firm to provide competitive assets in the space. Stoeckli, an ex-Sanofi senior executive, also outlines why the upside potential of Glenmark’s BEAT antibody technology platform is “remarkable”.
You may also be interested in...
Glenmark has snagged a top name in oncology from Gilead to lead its spin-out innovation business.
Glenmark’s innovation business will now be housed in a spin-out arm, based in the US, where the Indian parent believes the ecosystem is more conducive to cutting-edge R&D. The new structure could also potentially provide new opportunities to unlock value for the parent company.
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.